Critical Imaging Risks In GLP-1 And Neurology Studies: What You Need To Know

Imaging has become a pivotal component in evaluating safety and efficacy in clinical trials involving GLP-1 receptor agonists, particularly due to emerging concerns around ocular risks such as non-arteritic anterior ischemic optic neuropathy (NAION). Early engagement with imaging vendors during protocol development helps prevent costly delays and amendments, while standardized image acquisition protocols ensure data quality and consistency across sites. Comprehensive baseline ocular assessments are crucial, especially as GLP-1 studies increasingly recruit participants with metabolic risk factors that may predispose them to vascular complications. Operational challenges such as limited specialist availability, inconsistent imaging protocols, and variable exam standards (e.g., Snellen vs. ETDRS) require proactive management. Site capability assessments and clear imaging guidelines are essential to mitigate these issues.

By strategically planning imaging logistics and translating preclinical findings into clinically relevant endpoints, sponsors can enhance data integrity and reduce risk. As imaging grows in importance within GLP-1 and neurology trials, it must be treated not as a routine task but as a strategic pillar that safeguards participant safety and supports robust, reproducible outcomes.